Recent OSRH News
- CEO Statement to Shareholders • ACCESS Newswire • 05/12/2026 01:16:00 PM
- Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target • ACCESS Newswire • 05/05/2026 05:05:00 PM
- OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 • ACCESS Newswire • 04/30/2026 01:15:00 PM
- OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe • ACCESS Newswire • 04/29/2026 01:50:00 PM
- OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note • ACCESS Newswire • 04/09/2026 01:15:00 PM
- OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 • ACCESS Newswire • 03/30/2026 01:00:00 PM
- Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target • ACCESS Newswire • 03/27/2026 01:00:00 PM
- OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level • ACCESS Newswire • 03/23/2026 12:30:00 PM
- Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials • PR Newswire (US) • 03/19/2026 01:44:00 PM
- Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities • ACCESS Newswire • 03/19/2026 12:55:00 PM
- OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum • ACCESS Newswire • 03/05/2026 02:30:00 PM
- CEO Statement to Shareholders • ACCESS Newswire • 02/02/2026 02:50:00 PM
- OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries • ACCESS Newswire • 01/27/2026 01:30:00 PM
- Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch • PR Newswire (US) • 01/22/2026 02:55:00 PM
- Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform • PR Newswire (US) • 01/16/2026 02:20:00 PM
- Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones • PR Newswire (US) • 01/12/2026 01:05:00 PM
- Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings • PR Newswire (US) • 12/19/2025 04:50:00 PM
- Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement • Newsfile • 12/04/2025 08:19:00 PM
- Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months • PR Newswire (US) • 12/02/2025 02:53:00 PM
- Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal • AllPennyStocks.com • 11/21/2025 06:06:00 PM
- Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones • PR Newswire (US) • 11/21/2025 02:20:00 PM
- OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion • PR Newswire (US) • 11/14/2025 04:10:00 PM
- OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study • PR Newswire (US) • 11/06/2025 01:30:00 PM
- Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target • Newsfile • 10/20/2025 03:40:00 PM
- OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care • PR Newswire (US) • 10/14/2025 12:30:00 PM
